Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Unaudited Preliminary Results)
Reporting Period: Year ended 31 December 2015 and Quarter ended 31 December 2015
Key Strategic Event: The year included the completion of the Novartis transaction on 2 March 2015, involving the disposal of the Oncology business and the acquisition of the Vaccines and Consumer Healthcare businesses. This restructuring fundamentally altered the Group's segment reporting and financial composition.
Key Financial Metrics
| Metric | 2015 Full Year (£m) | 2015 Q4 (£m) | 2015 Growth (CER%) |
|---|---|---|---|
| Turnover | 23,923 | 6,286 | +6% (FY) / +4% (Q4) |
| Core Operating Profit | 5,729 | 1,357 | -9% (FY) / -18% (Q4) |
| Total Operating Profit | 10,322 | (254) | >100% (FY) / >(100)% (Q4) |
| Core EPS | 75.7p | 18.1p | -15% (FY) / -28% (Q4) |
| Total EPS | 174.3p | (7.3)p | >100% (FY) / >(100)% (Q4) |
| Net Debt | 10,727 | 10,727 | N/A |
| Free Cash Flow | (155) | 553 | N/A |
Note: CER = Constant Exchange Rate. Total results include significant non-core items related to the Novartis transaction.
Material Changes vs. Prior Period
- Revenue Mix: Group turnover grew 6% on a reported basis. Pharmaceuticals declined 7% (driven by Oncology disposal and generic competition), while Vaccines grew 19% and Consumer Healthcare grew 44% (driven by the Novartis acquisition).
- Profitability: Core operating profit declined 9% (CER) due to the lower margin profile of the acquired businesses and the loss of the high-margin Oncology business. However, Total Operating Profit surged over 100% due to a £9.2 billion gain on the disposal of the Oncology business.
- EPS Volatility: Core EPS fell 15% (CER) reflecting short-term dilution from the transaction. Total EPS increased over 100% due to transaction gains, offset by restructuring charges and contingent consideration revaluations.
- Cash Flow: Net debt decreased from £14.4 billion to £10.7 billion, primarily due to net cash proceeds of £10.0 billion from the Oncology sale. Free cash flow turned negative for the full year (-£155m) due to legal settlements and restructuring costs, though Q4 showed a positive inflow of £553m.
Guidance, Outlook, and Risks
- 2016 Guidance: GSK expects Core EPS percentage growth to reach double digits on a CER basis in 2016. If exchange rates hold at January 2016 averages, this could add an estimated +5% to Sterling Core EPS growth.
- Dividends: Confirmed an ordinary dividend of 80p for 2015 (paid in four tranches) and a special dividend of 20p. The Group expects to maintain an 80p ordinary dividend for 2016 and 2017.
- New Product Targets: Sales of new pharmaceutical and vaccine products reached £2 billion in 2015. The target of £6 billion in annual revenue from new products is now expected to be met by 2018, two years ahead of the previous 2020 target.
- R&D Pipeline: A portfolio of ~40 assets is driving long-term performance. Key milestones expected in 2016/2017 include Shingrix (shingles vaccine), sirukumab (RA), and cabotegravir (HIV). The estimated R&D rate of return remains at 13%.
- Risks and Contingencies:
- Contingent Consideration: A liability of £3.4 billion is recognized for contingent consideration to Shionogi regarding ViiV Healthcare, with further revaluations expected.
- Put Options: GSK intends to recognize a liability of approximately £2 billion for put options held by Pfizer and Shionogi in ViiV Healthcare in Q1 2016.
- Legal Matters: Aggregate provision for legal disputes was £0.4 billion. Significant litigation and tax investigations remain ongoing.
- Currency: Strong Sterling against the Euro and Yen negatively impacted reported results, though the US Dollar weakened against Sterling.
Investor Verification Checklist
- Novartis Integration: Verify the realization of the projected £3 billion in annual cost savings by end-2017 and the integration progress of Vaccines and Consumer Healthcare.
- ViiV Healthcare Liabilities: Monitor the Q1 2016 recognition of the £2 billion put option liability and the ongoing revaluation of the £3.4 billion contingent consideration to Shionogi.
- Respiratory Portfolio Transition: Track the decline of Seretide/Advair sales against the growth of new Ellipta products (Relvar, Breo, Anoro, Incruse) to ensure the portfolio transition offsets patent expiries.
- 2016 Core EPS Growth: Assess whether the double-digit Core EPS growth target is achievable given the challenging macro-economic environment and currency headwinds.
- Legal Provisions: Review updates on the £0.4 billion legal provision and potential exposure from ongoing product liability and government investigations.